

MANUFACTURERS OF PARENTERAL PRODUCTS [CIN: L24230GJ1980PLC003843]

ADDRESS: 401 – ABHISHREE, OPP. OM TOWER, SATELLITE ROAD, AHMEDABAD – 380 015 GUJARAT, INDIA TEL.: +91 (79) 26925716, 26925719 FAX: +91 (79) 2692\$710 Email: denischem401@gmail.com



12th February, 2021

BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400 001

Company Code No. 537536

Dear Sirs,

Sub: Submission of Unaudited Financial Results for the Quarter ended on 31st December, 2020

We refer to our letter dated 1st February, 2021 informing the date of Meeting of the Board of Directors of the Company. Please note that the Board of Directors in their meeting held today, have taken on record the Unaudited Financial Results for the quarter ended on 31st December, 2020

We are enclosing herewith copy of the said Unaudited Financial Results for the quarter ended on 31st December, 2020 along with Limited Review Report thereon.

This is as per Regulation – 33 of the SEBI (LODR) Regulations, 2015.

Thanking you,

Yours faithfully, for DENIS CHEM LAB LIMITED

loot

HÍMANSHU C. PATEL MANAGING DIRECTOR (DIN : 00087114)

Encl: As above.



MANUFACTURERS OF PARENTERAL PRODUCTS [CIN: L24230GJ1980PLC003843]



ADDRESS: 401 – ABHISHREE, OPP. OM TOWER, SATELLITE ROAD, AHMEDABAD – 380 015 GUJARAT, INDIA TEL.: +91 (79) 26925716, 26925719 FAX: +91 (79) 26925710 Email: denischem401@gmail.com

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 31ST DECEMBER, 2020

	Particulars	Quarter ended on			9 Months ended on (Cumulative)		Previous Year ended
(Refer Notes Below)		31-12-2020 (Unaudited)	30-09-2020 (Unaudited)	31-12-2019 (Unaudited)	31-12-2020 (Unaudited)	31-12-2019 (Unaudited)	on 31-03-2020 (Audited)
2	Other income	1.85	10.59	2.94	27.62	36.78	28.25
3	Total Income (1+2)	3054.19	2782.50	3638.79	8187.63	10521.94	13642.83
4	Expenses	in the conserve					
	a. Cost of Materials consumed	1491.26	1389.17	1702.81	3987.55	4978.34	6287.59
	b. Purchases of stock-in-trade	-	-		-	-	-
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	61.69	19.20	36.71	26.17	47.21	(131.04)
	d. Employee benefits expense	269.00	255.19	302.07	759.87	888.40	1220.06
	e. Finance costs	34.67	39.78	68.56	120.04	210.49	289.18
	f. Depreciation & amortisation expense	150.73	149.42	161.44	441.14	481.87	666.46
	g. Other expenses	849.56	836.31	1195.93	2498.41	3384.33	4737.93
	Total Expenses	2856.91	2689.07	3467.52	7833.18	9990.64	13070.18
5	Profit / (Loss) before exceptional items and tax (3-4)	197.28	93.43	171.27	354.45	531.30	572.65
6	Exceptional items	-	-	-		+	-
7	Profit / (Loss) before tax (5+6)	197.28	93.43	171.27	354.45	531.30	572.65
8	Tax expense:						
	Current tax	27.47	14.22	36.00	88.57	116	122.42
	Deferred tax	(26.69)	66.45	8.40	10.60	10.73	28.83
9	Profit (Loss) for the period from continuing operations (7-8)	196.50	12.76	126.87	255.28	404.57	421.40
10	Profit/(loss) from discontinuing operations before Tax	-	-	-		•	
11	Tax expense of discontinuing operations	-	÷.	-			-
12	Profit/(loss) from Discontinuing operations (after tax) (10-11)			-		-	
13	Profit / (Loss) for the period (9+12)	196.50	12.76	126.87	255.28	404.57	421.40



MANUFACTURERS OF PARENTERAL PRODUCTS [CIN: L24230GJ1980PLC003843]



ADDRESS: 401 – ABHISHREE, OPP. OM TOWER, SATELLITE ROAD, AHMEDABAD – 380 015 GUJARAT, INDIA TEL.: +91 (79) 26925716, 26925719 FAX: +91 (79) 26925710 Email: denischem401@gmail.com

Particulars		Quarter ended on			9 Months ended on (Cumulative)		Previous Year ended
		31-12-2020	30-09-2020	31-12-2019	31-12-2020	31-12-2019	on 31-03-2020 (Audited)
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	
14	Other Comprehensive Income						
	Items that will not be reclassified subsequently to profit or loss						
	Gain/(loss) on re-measurement of defined benefit plan	-	-	-		-	13.49
	Income tax relating to items that will not be reclassified to profit or loss	-		-	-	-	(3.75)
	Items that will be reclassified subsequently to profit or loss						
	Income tax relating to items that will be reclassified to profit or loss						
	Other Comprehensive Income, net of tax			-		-	9.74
15	Total Comprehensive Income for the period (13+14)	196.50	12.76	126.87	255.28	404.57	431.14
16	Paid-up equity shares capital (Face Value per share Rs. 10/-)	1387.67	1387.67	1387.67	1387.67	1387.67	1387.67
17	Reserves excluding Revaluation Reserves				le contra		4521.05
18	Earnings Per Share of Rs. 10/- each (for continuing operations)						
4	- Basic	1.42	0.09	0.91	1.84	2.91	3.03
	- Diluted	1.42	0.09	0.91	1.84	2.91	3.03
19	Earnings Per Share of Rs. 10/- each (for discontinued operations)						
	- Basic	-	-		-	-	-
	- Diluted	-	· · · · · · · · · · · · · · · · · · ·		24	•	-
20	Earnings Per Share of Rs.10/- each (for discontinued & continuing operations)						
	- Basic	1.42	0.09	0.91	1.84	2.91	3.03
	- Diluted	1.42	0.09	0.91	1.84	2.91	3.03



MANUFACTURERS OF PARENTERAL PRODUCTS [CIN: L24230GJ1980PLC003843]



ADDRESS: 401 – ABHISHREE, OPP. OM TOWER, SATELLITE RØAD, AHMEDABAD – 380 015 GUJARAT, INDIA TEL.: +91 (79) 26925716, 26925719 FAX: +91 (79) 26925710 Email: <u>denischem401@gmail.com</u>

Notes:

Notes:

- 1. These unaudited financial results have been prepared in accordance with the Indian Accounting Standard (referred to as "Ind AS") prescribed under section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standard) Rules as amended from time to time. These financial results were reviewed by the audit committee and thereafter have been approved by the board of directors at its meeting held on Friday, February 12, 2021. The Statutory Auditors have conducted limited review on these results and issued an unmodified opinion on the same.
- The Company is operating only in one segment i.e. manufacturing & sales of transfusion solutions in bottles. Hence segment reporting is not given.
- 3. The figures for quarter ended December 31, 2020 are balancing figures between the unaudited figures of nine months ended on December 31, 2020 and the reviewed year-to-date figures up to half year ended on September 30, 2020.
- 4. On September 20, 2019, vide the Taxation Laws (Amendment) Ordinance 2019, the Government of India inserted Section 115BAA in the Income Tax Act, 1961 which provides domestic companies a non-reversible option to Pay corporate tax at reduced rates effective April 01,2019 subject to certain conditions. The Company has made an assessment of the impact of the Taxation Laws (Amendment) Act, 2019 and decided to continue with the existing tax structure until utilization of accumulated Minimum Alternate Tax (MAT) Credit.
- 5. The Indian Parliament has approved the Code on Social Security, 2020 which would impact the contributions by the Company towards Provident Fund and Gratuity. The Ministry of Labour and Employment has released draft rules for the Code on Social Security, 2020 on November 13, 2020 and has invited suggestions from the stakeholders which are under active consideration by the Ministry. The Company will assess the impact and its evaluation once the subject rules are notified and will give appropriate impact in its financial statements in the period in which, the said code become effective including related rules framed thereunder to determine the financial impact are published.

Figures for the previous period/year have been regrouped/rearranged to make the same comparable with current period/year figures.

for DENIS CHEM LAB LIMITED

logh

HIMANSHU C. PATEL MANAGING DIRECTOR (DIN : 00087114)

Date: 12th February, 2021 Place: Ahmedabad



H K Shah & Co. CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on quarter and year to date Unaudited Standalone Financial Results of DENIS CHEM LAB LIMITED pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

To The Board of Directors of **DENIS CHEM LAB LIMITED**

- We have reviewed the accompanying statement of unaudited standalone financial results of **DENIS CHEM LAB LIMITED** ("the Company") for the quarter and nine months ended December 31, 2020 being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,2015, as amended ("the Statement").
- 2. This statement which is the responsibility of the Company's management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting", as prescribed under Section 133 of the Companies Act,2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.
- 3. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410," *Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free from material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as stated above nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards prescribed under Section133 of the Companies Act,2013,read with relevant rules issued thereunder and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

